Differences between afatinib and osimertinib: Which one is more effective?

Afatinib and Osimertinib (Osimertinib) are both targeted drugs used to treat EGFR-mutated non-small cell lung cancer (NSCLC) . Although they both belong to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) category, there are significant differences in molecular mechanisms, target selection, efficacy performance, side effects and resistance mechanisms. In response to the common question of "Which treatment is more effective?", a comprehensive analysis must be conducted based on multiple dimensions such as the patient's genetic mutation type, medication timing, individual tolerance, etc., and cannot simply be classified as superior or inferior.

From the mechanism of action, afatinib belongs to the second generationEGFR-TKI, which has the characteristics of irreversibly inhibiting multiple members of the HER family, including EGFR (HER1), HER2 and HER4, which gives it certain advantages in covering a wide range of mutation types, especially EGFR 19 deletion, L858R mutation and certain rare mutations (such as G719X, S768I, L861Q). It shows good targeting effect. Osimertinib is a third-generation EGFR-TKI, specifically designed to overcome patients with T790M resistance mutations. It also has strong inhibitory ability against classic sensitive mutations (19del, L858R), and has lower affinity for normal tissue, so the side effects are milder.

In terms of efficacy, if "overall survival time" and "progression-free survival" are used as the measurement criteria, osimertinib has shown better results than the first- and second-generation EGFR-TKIs in multiple clinical studies around the world. Especially in the first-line treatment of EGFR mutation-positive NSCLC patients, osimertinib can not only significantly prolong the progression-free survival (PFS) of patients, but its ability to control brain metastases is also much stronger than afatinib. A large amount of clinical evidence shows that osimertinib can penetrate the blood-brain barrier and control intracranial lesions, thereby reducing the risk of brain metastasis progression, which has a decisive advantage for advanced patients.

However, it is worth noting that in specific rare EGFR mutation types, afatinib performs better than osimertinib. For example, for atypical mutations such as G719X, L861Q, and S768I, studies have shown that afatinib has a higher treatment response rate and disease control rate. In addition, afatinib has shown good disease stability in some Asian patients, especially after first-line treatment, it still has the significance of conservative treatment.

In terms of side effects, common adverse reactions of afatinib include diarrhea, rash, stomatitis, paronychia, etc., which may be more obvious especially in the initial treatment and need to be managed through dose adjustment or adjuvant treatment. Osimertinib is more popular in terms of clinical tolerance due to its more specific target and mild side effects. Common side effects include mild diarrhea, fatigue and dry skin, which usually do not interfere with patients' daily life.

In terms of drug accessibility and medical insurance, both afatinib and osimertinib are currently on the market in mainland China and have been included in the national medical insurance directory. Afatinib is more affordable, with a box of 40 mg and 7 tablets costing around RMB 1,000, while osimertinib (80 mg and 30 tablets) costs around RMB 4,000. Although the price is higher, it is still recommended by most doctors as a first-line drug due to its superior efficacy and mild adverse reactions.

In general, if the patient has common sensitive mutations in EGFR, osimertinib has better first-line treatment performance and can effectively prolong progression-free survival time and reduce brain metastasis; while for some patients with rare mutations, afatinib may still be a more accurate choice.

Reference materials:https://www.giotrif.com/